Severe Autoimmune Encephalitis
Conditions
Keywords
severe autoimmune encephalitis, prediction model, plasma exchange therapy, plasma adsorption therapy, targeted immunotherapy
Brief summary
A prospective study aims to establish a multicenter clinical diagnosis and treatment database for patients with autoimmune encephalitis (AE). The study will analyze the characteristics of disease progression, changes in immune-inflammatory markers, immunotherapy regimens, and patient outcomes. It seeks to identify clinical indicators for the early recognition of severe AE patients, develop and validate a predictive model for severe AE, and explore effective treatment strategies to rapidly control disease progression during the acute phase of severe AE.
Detailed description
To develop and validate a predictive model for severe autoimmune encephalitis (AE), a prospective multicenter study will be conducted. Clinical data of hospitalized AE patients will be collected consecutively, and a multicenter integrated database will be established. This database will include information on the characteristics of disease progression, changes in blood and cerebrospinal fluid immune-inflammatory markers, specific immunotherapy regimens, patient outcomes, and long-term prognoses. The study will analyze the clinical and immunological characteristics of AE patients, identify clinical indicators for early recognition of severe AE, and develop and validate a predictive model for severe AE. Additionally, the study will evaluate the efficacy of early plasma exchange/plasma adsorption therapy and targeted immunotherapy on AE outcomes and long-term prognosis, aiming to explore effective treatment strategies for rapidly controlling disease progression in the acute phase of severe AE.
Interventions
OTHERNo Intervention: Observational Cohort
No intervention
Sponsors
Xuanwu Hospital, Beijing
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
14 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* age 14-80 years * no restriction on gender * meets the diagnostic criteria for confirmed AE, with a clearly identified pathogenic antibody * within 3 months of AE * patients voluntarily sign the informed consent form; if unable to express their will or sign, the consent form can be signed by a close relative on their behalf
Exclusion criteria
* no lumbar puncture performed for CSF antibody testing * did not receive immunotherapy * pre-onset modified Rankin Scale (mRS) score ≥3
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CASE | 2 months of enrollment | The unabbreviated scale title is the clinical assessment scale for autoimmune encephalitis. The CASE includes a total score of 0-27.The higher the score, the worse the prognosis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CASE | 1 month of enrollment | The unabbreviated scale title is the clinical assessment scale for autoimmune encephalitis. The CASE includes a total score of 0-27.The higher the score, the worse the prognosis. |
| mRS | 1 months, 2 months of enrollment | The unabbreviated scale title is modified Rankin Scale. The mRS includes 0-6, and the higher the score, the worse the prognosis. |
| GCS | 1 months, 2 months of enrollment | The unabbreviated scale title is Glasgow coma score. The GCS tested 3 components: eye opening response, verbal response and motor response, with a total score of 15. The lower the score, the more severe the brain damage and the deeper the degree of DOC. |
| Prognostic scores (CASE) | 6 months, 12 months of enrollment | The unabbreviated scale title is the clinical assessment scale for autoimmune encephalitis. The CASE includes a total score of 0-27.The higher the score, the worse the prognosis. |
| Prognostic scores (mRS) | 6 months, 12 months of enrollment | The unabbreviated scale title is modified Rankin Scale. The mRS includes 0-6, and the higher the score, the worse the prognosis. |
Contacts
Primary ContactYan Zhang
Outcome results
None listed